Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.56 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17888469 | 1.00 | RAB9A (0.68) | RAB9AHPGDNPC1CYP1A2CYP2C19 | |
| SCHEMBL14679163 | 0.91 | RAB9A (0.62) | RAB9AHPGDNPC1CYP1A2CYP2C19 | |
| SCHEMBL12045094 | 0.89 | MAPK1 (0.57) | RAB9AHPGDNPC1CYP1A2CYP2C19 | |
| SCHEMBL3242515 | 0.86 | MAPK1 (0.57) | RAB9AHPGDNPC1CYP1A2CYP2C19 | |
| SCHEMBL3242517 | 0.86 | MAPK1 (0.57) | RAB9AHPGDNPC1CYP1A2CYP2C19 | |
| SCHEMBL17886791 | 0.86 | MAPK1 (0.57) | RAB9AHPGDNPC1CYP1A2CYP2C19 | |
| SCHEMBL3315567 | 0.85 | MAPK1 (0.56) | RAB9ANPC1OPRK1MAPK1CHEK1 | |
| SCHEMBL14023410 | 0.85 | CHEK1 (0.57) | RAB9AHPGDNPC1CYP1A2CYP2C19 | |
| SCHEMBL1163022 | 0.85 | MAPK1 (0.59) | RAB9ANPC1SMN1; SMN2OPRK1MAPK1 | |
| SCHEMBL1163023 | 0.85 | MAPK1 (0.59) | RAB9ANPC1SMN1; SMN2OPRK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-2123769-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8338142-B2 | Method for producing optically active 3-aminopiperidine or salt thereof | KANEKA CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2123769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | Kaneka Corporation (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | RAB9A 3888/4885HPGD 994/4885NPC1 3586/4885 |
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | RAB9A 1208/4885HPGD 479/4885NPC1 3644/4885 |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | RAB9A 1208/4885HPGD 479/4885NPC1 3644/4885 |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | RAB9A 1208/4885HPGD 479/4885NPC1 3644/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | RAB9A 3888/4885HPGD 994/4885NPC1 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.